Estimating the Use of Resources and the Costs of Treating Patients With Asthma in the Autonomous Community of Valencia
Launched by ASTRAZENECA · Apr 30, 2010
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Ambulatory patients (Primary and Specialized Care)
- • Patients with a diagnose of asthma in the Outpatients' Electronic Health Record \[Historia Clínica Ambulatoria electrónica (SIA + GAIA) database
- Exclusion Criteria:
- • Patients who have participated in a clinical trial in the last 12 months.
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Valencia, , Spain
Alcoy, Alicante, Spain
Xativa, Valencia, Spain
Vila Real, Castellón, Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials